Skip to main content
S&P 5007,551.81-0.45%DOW51,461.90-1.21%NASDAQ25,978.42-0.01%BTC$76,346.00+0.85%ETH$2,420.07+0.87%GOLD$4,327.00-1.38%OIL$101.32-1.08%
Smart Investors Daily
CT

NASDAQ · CTKB

Cytek Biosciences, Inc.

Healthcare · Medical - Devices

$4.89

Up+$0.04 (+0.82%)

Updated Sep 17, 2026, 1:54 AM

SID Score

5.2/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
636.75M
P/E ratio
-98.76
Dividend yield
0.00%
52-week range
$3.28 – $6.18
Volume
1.12M
Avg. volume
1.17M

Price performance

CTKB price history

1M range · 19 trading sessions · Daily adjusted prices

CTKB closed at $4.89 after 19 trading sessions, up 4.04% for the selected period.

Last close
$4.89
Period change
+4.04%
Period low
$4.44
Period high
$4.89
Daily close
View OHLC price history
CTKB OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 15, 2026$4.81$5.02$4.80$4.891.12M
Sep 14, 2026$4.62$4.86$4.57$4.831.17M
Sep 11, 2026$4.61$4.64$4.485$4.61897.71K
Sep 10, 2026$4.69$4.70$4.51$4.532.42M
Sep 9, 2026$4.59$4.75$4.55$4.73810.26K
Sep 8, 2026$4.64$4.68$4.54$4.62649.72K
Sep 4, 2026$4.67$4.7285$4.62$4.70478.23K
Sep 3, 2026$4.70$4.77$4.515$4.70485.32K
Sep 2, 2026$4.66$4.78$4.58$4.69564.63K
Sep 1, 2026$4.775$4.805$4.55$4.62629.43K
Aug 31, 2026$4.63$4.805$4.48$4.78958.63K
Aug 28, 2026$4.62$4.71$4.48$4.68796.31K
Aug 27, 2026$4.57$4.735$4.56$4.62651.35K
Aug 26, 2026$4.53$4.58$4.509$4.57437.7K
Aug 25, 2026$4.45$4.58$4.36$4.58605.08K
Aug 24, 2026$4.80$4.84$4.29$4.44943.49K
Aug 21, 2026$4.69$4.83$4.59$4.81820.26K
Aug 20, 2026$4.63$4.78$4.615$4.66800.61K
Aug 19, 2026$4.67$4.92$4.67$4.701.04M

Latest CTKB news

The latest Smart Investors Daily articles mentioning CTKB.

Stock researchCompany · Overview

CTKB research

Overview

Company profile and research snapshot.

Company profile

Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Cytek Aurora and Northern Lights systems, are the first full-spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its FSP platform addresses the inherent limitations of other technologies by providing a higher density of information with greater sensitivity, more flexibility, and increased efficiency, all at a lower cost for performance. Geographically, the company generates a majority of its revenue from the United States.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$6.00
Implied upside
—
Analysts
—
CTKB recent ratings
DateFirmRatingTarget
May 13, 2026Stephens & Co.Overweight—
May 12, 2026Morgan StanleyEqual-Weight—
Jan 8, 2026TD CowenBuy—
Nov 11, 2025Piper SandlerOverweight—
May 28, 2025Morgan StanleyEqual-Weight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 9, 2026

Sysmex Europe and Cytek® Biosciences Collaborate to Expand Access to Advanced Clinical Flow Cytometry

Complementary Technologies Deliver an Integrated, End-to-End Clinical Flow Cytometry Workflow for Laboratories Across Europe Cytek Biosciences and Sysmex Europe Collaborate Cytek Biosciences and Sysmex Europe have signed an agreement establishing a strategic collaboration to enhance clinical flow cytometry workflows and expand access to innovative diagnostic solutions. By combining their complementary technologies, the collaboration will provide an integrated, end-to-end clinical flow cytometry

Yahoo · Sep 9, 2026

Cytek’s (CTKB) Instruments Keep Selling While Losses Keep Growing

On August 5, Cytek Biosciences (NASDAQ:CTKB) reported financial results for the second quarter ended June 30, and the report reads like two different companies at once. Revenue climbed, margins widened, and the installed base of instruments kept expanding. At the same time, the net loss more than doubled from a year earlier and adjusted EBITDA […]

Yahoo · Sep 3, 2026

Cytek® Biosciences Highlights the Expanding Role of Spectral Flow Cytometry in Clinical Research at ESCCA and ICCS

FREMONT, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- As clinical laboratories seek deeper cellular insights, greater efficiency, and more streamlined approaches to cell analysis, spectral flow cytometry leader Cytek Biosciences, Inc. (Nasdaq: CTKB) will showcase its advanced solutions at two leading clinical cytometry events this fall: the European Society for Clinical Cell Analysis (ESCCA) 2026 Conference and ICCS 2026, the 41st Annual International Clinical Cytometry Meeting & Course. Set apart

Yahoo · Sep 1, 2026

Cytek Biosciences to Participate in Upcoming Investor Conferences

FREMONT, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the following investor conferences.Wells Fargo 21st Annual Healthcare Conference in Boston, MACFO William McCombe will be participating in investor meetings on Tuesday, September 8, 2026Morgan Stanley 24th Annual Global Healthcare Conference in New York, NYCEO Wenbin Jiang and CFO William McCombe will be partic

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By